Trials / Terminated
TerminatedNCT03879798
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
A Phase I/II Study of DS-3201b, an EZH1/2 Inhibitor, in Combination With Irinotecan in Patients With Recurrent Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-3201b | 100 mg daily |
| DRUG | irinotecan | Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle. |
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2023-05-02
- Completion
- 2023-05-02
- First posted
- 2019-03-19
- Last updated
- 2024-10-10
- Results posted
- 2024-10-10
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03879798. Inclusion in this directory is not an endorsement.